Biohaven's antiviral antibody conjugate is effective in vitro

By The Science Advisory Board staff writers

February 22, 2021 -- Biohaven Pharmaceutical's hyperimmune globulin mimic (HGM), developed on its proprietary multimodal antibody therapy enhancer (MATE) platform, has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including emerging variants.

The preclinical experiments show that the candidate, BHV-1200, substantially reduced viral entry into cells. The candidate also showed broad and potent antiviral activity against the wildtype SARS-CoV-2 spike protein, as well as those associated with reduced susceptibility to therapeutic monoclonal antibodies and recent strains.

In vitro data indicated that BHV-1200 may activate important immune system components including antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC).

The MATE conjugation technology uses a class of synthetic peptide binders to target the spike protein of SARS-CoV-2. The binders are subsequently conjugated to commercially available intravenous immunoglobulin. The synthetic binders were designed to establish a wider area and number of contacts with the spike protein.

The development of the COVID-19 MATE program is supported by the Bill and Melinda Gates Foundation.

Biohaven acquires Kleo Pharmaceuticals
Biohaven Pharmaceuticals has completed its acquisition of Kleo Pharmaceuticals in a deal worth $20 million to advance bispecific compounds that emulate...

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter